When 42-year-old Katarzyna sat in the OCT scanner at a clinic in Warsaw, she didn’t know her eye would soon reveal secrets no machine had seen before. Beneath the surface of her cornea, nerve fibers thinner than a human hair lay coiled like delicate threads—now visible in unprecedented clarity, thanks to a breakthrough called STOC-T. Developed by Prof. Maciej Wojtkowski and his team at the International Centre for Translational Eye Research (ICTER) in Warsaw, this new imaging method is transforming how doctors see the living eye, cutting through optical noise to reveal cellular details once lost in grainy static.
For decades, optical coherence tomography (OCT) has been a cornerstone of eye care, allowing non-invasive, layer-by-layer views of the retina. It’s instrumental in catching diseases like glaucoma, diabetic retinopathy, and macular degeneration before vision fades. But even OCT has limits. When light scatters inside the eye, it creates “optical crosstalk”—a kind of visual static that blurs fine structures. The choroid, photoreceptors just a few micrometers wide, and corneal nerves critical for healing after surgery often vanish into the noise. Early disease signs hide in that blur.
STOC-T changes the game. Rather than cleaning up images after the scan, it reshapes how light is captured. By cycling through different phase masks—patterns that alter the illumination light’s phase—the system collects multiple signal readings. Scattered, noisy light shifts unpredictably with each mask, while true tissue signals stay consistent. When averaged, the noise cancels out and the real structure emerges, sharper than ever. In trials, STOC-T has successfully visualized individual nerve bundles in the cornea and improved contrast in retinal layers by up to 40%, a leap that could redefine early diagnosis.
The impact is already rippling through ophthalmology. At ICTER, researchers are using STOC-T to study nerve regeneration in diabetic patients and subtle changes in the retinal pigment epithelium—clues that may predict macular degeneration years before symptoms appear. Unlike post-processing filters, STOC-T’s noise reduction happens at the source, preserving data integrity in a way software enhancements cannot.
“This is not about prettier pictures,” says Wojtkowski. “It’s about seeing what was always there but hidden by noise.” As clinical trials expand and the technology moves toward commercial integration, the promise grows: millions of eyes could soon be scanned with a clarity once thought impossible. For patients like Katarzyna, that means not just clearer images—but clearer futures.